Navigation Links
HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
Date:5/23/2012

FRAMINGHAM, Mass., and SYDNEY, May 23, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that it has received an expanded European label for long-term use of the HeartWare® Ventricular Assist System in all patients at risk of death from refractory, end-stage heart failure.

"This label extension is similar to the 'Destination Therapy' indication in the United States, and having that designation now outside the U.S. provides our international customers with additional flexibility as they treat those patients who might not be eligible for heart transplantation," stated Doug Godshall, President and Chief Executive Officer.  "This new label reflects the positive long-term survival data from our international trial, as well as the longer utilization times of ventricular assist devices in Europe."

In 2009, HeartWare received CE Marking for use of the HeartWare® Ventricular Assist System in patients as a bridge to heart transplantation.  Today, more than 2,000 patients around the globe have been implanted with the HeartWare Ventricular Assist System.  Earlier this month, HeartWare reported 91 customer sites in 25 countries outside of the United States, in addition to 50 clinical sites within the U.S.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery general
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... health affects a man,s lifestyle, and if he wants to ... he should address any hearing loss he may be experiencing. ... Institute (BHI) is delivering to men around the country ... leads up to and includes Father,s Day. This year, National ... To help men address their hearing health ...
(Date:5/23/2013)... recently published clinical study conducted at TOPS Comprehensive Breast ... that 3D mammography (breast tomosynthesis) significantly reduces unnecessary recalls ... study, "Implementation of Breast Tomosynthesis in a Routine Screening ... Stephen L. Rose , MD, and published in ... Roentgenology (AJR). The AJR is the scientific journal ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... , GENEVA, Switzerland, May 2, 2007 – Merck,Serono ... data on,safinamide, a new agent in Phase III ... presented by Professor,Fabrizio Stocchi at the American Academy ... These data are from a,6-month (24 weeks), randomized, ...
... THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 30, 2007 ... from a pivotal Phase 3,trial which ... human,monoclonal antibody directed against the epidermal ... (PFS) compared,to best supportive care (BSC) ...
Cached Medicine Technology:Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 2Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 3Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 4Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 5Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 2Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 3Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 4Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 5Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 6
(Date:5/25/2013)... Idaho (PRWEB) May 25, 2013 A ... prevalent type of peripheral neuropathy. According to neuropathy expert ... , it is estimated that the disorder affects almost ... common complication arising from Diabetes. The high blood sugar ... Diabetes and patients suffering from it usually tend to ...
(Date:5/25/2013)... (HealthDay News) -- Many viruses and parasites that affect ... -- a bacteria-borne illness than can result in liver ... parks, according to a veterinarian. These germs ... the air, said Dr. Susan Nelson, a clinical associate ... of these serious diseases can be fatal, even with ...
(Date:5/25/2013)... 25, 2013 The report “Global ... Types, Functions, Applications, Ingredients, Shell Materials, Packaging, & ... global food encapsulation market with analysis and forecasting ... also identifies the driving and restraining factors for ... trends, opportunities, and challenges. The market is segmented ...
(Date:5/25/2013)... May 25, 2013 Studies from Johns ... are carrying excessive weight and their inability to get ... simply losing weight can naturally relieve many symptoms. ... improvement in sleep quality was significantly associated with overall ... study dated November 6th, 2012, researchers monitored ...
(Date:5/25/2013)... Sun City Center, FL (PRWEB) May 25, 2013 ... years, is one of many of the NALA’s businesses throughout ... Owner, Craig Amshel chose to participate in the nationwide event ... served as a Lieutenant Colonel in the Army. He said, ... work in the community I serve, but I live here ...
Breaking Medicine News(10 mins):Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2
... new study by the NYU Cancer Institute, an NCI-designated ... leukemia, a type of blood cancer that affects children ... an intracellular communication pathway called Notch led to the ... this disease. Notch has already been implicated in another ...
... nine-years-old can start to show an increased risk of future heart ... the May issue of Acta Paediatrica . ... studied 223 children 123 boys and 100 girls with ... over four days. They found that the children who were ...
... appears to have a genetic basis, at least in part. ... small reins) plays a key role in this process, as ... Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have now shown. ... to nicotine ( Neuron , May,12, 2011, Vol. 70, Issue ...
... 12 (HealthDay News) -- Music hath charms to protect the ... Northwestern University researchers who compared adults aged 45 to 65 ... to confer advantages in at least two important functions known ... hear speech in noise," study co-author Nina Kraus, director of ...
... at the edge of an ice hole, an Antarctic emperor ... the bird descends and may not emerge again for another ... stores the blood, lungs and myoglobin in muscle ... the surface, lactate begins appearing in the penguin,s blood and ...
... a smoker,s chance of quitting, according to new research published ... This study is the first to assess the effectiveness of ... The research, which was carried out by scientists at the ... enrolled in a programme to help them quit smoking. ...
Cached Medicine News:Health News:Study reveals origins of a cancer affecting the blood and bone marrow 2Health News:Lack of exercise linked to higher heart disease risk in healthy children as young as 9 2Health News:Reining in nicotine use 2Health News:Musicians Maintain Memory, Hearing as They Age 2Health News:Penguins continue diving long after muscles run out of oxygen 2Health News:Penguins continue diving long after muscles run out of oxygen 3
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
... With the Symphony family of Pacemakers, Ela ... market. Symphony, lighter than a passport, will ... using new technologies, and delivering powerful monitoring. ... for dual-chamber and atrial tracking modes in ...
Medicine Products: